The Goldman Sachs Group, Inc. : The upward trend is being put into question
Entry price | Target | Stop-loss | Potential |
---|
$201.66 |
$182.5 |
$211.2 |
+9.5% |
---|
Goldman Sachs Group's shares show signs of a reversal to the downside. The technical chart pattern has deteriorated and suggests a continuation of the decline.
Strengths● Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
● Considering the small differences between the analysts' various estimates, the group's business visibility is good.
● The group usually releases upbeat results with huge surprise rates.
● Its low valuation, with P/E ratio at 8.89 and 8 for the ongoing fiscal year and 2020 respectively, makes the stock pretty attractive with regard to earnings multiples.
Weaknesses● According to Thomson-Reuters' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
● For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
● Analysts covering the stock have recently lowered their earnings forecast.
● For the last few months, analysts have been revising downwards their earnings forecast.
The content herein constitutes a general investment recommendation, prepared in accordance with provisions aimed at preventing market abuse by Surperformance, the publisher of MarketScreener.com. More specifically, this recommendation is based on factual elements and expresses a sincere, complete, and balanced opinion. It relies on internal or external data, considered reliable as of the date of their release. Nevertheless, this information, and the resulting recommendation, may contain inaccuracies, errors, or omissions, for which Surperformance cannot be held responsible. This recommendation, which in no way constitutes investment advice, may not be suitable for all investor profiles. The reader acknowledges and accepts that any investment in a financial instrument involves risks, for which they assume full responsibility, without recourse against Surperformance. Surperformance commits to disclosing any conflict of interest that may affect the objectivity of its recommendations.